Investors & Media
Our science-driven strategy allows us to advance our programs with sound execution and ultimately bring long-term value to patients. Follow the journey of our dedicated scientists and drug developers or learn how you can contribute to our mission.
Our science-driven strategy allows us to advance our programs with sound execution and ultimately bring long-term value to patients. Follow the journey of our dedicated scientists and drug developers or learn how you can contribute to our mission.
Investor Opportunities
Contact UsLatest News
1ST Biotherapeutics, Inc., Announces Positive Phase I Data of c-Abl Inhibitor in Neurodegeneration
October 18, 2022
2022년 임시주주총회 소집공고(정정)
August 24, 2022
2022년 임시주주총회 소집공고
August 23, 2022
임시주주총회 기준일 공고
August 5, 2022
제 6기 정기주주총회 소집공고
March 16, 2022
“퍼스트바이오 면역항암제 후보물질 KDDF 신약개발 지원과제 선정”
November 1, 2021
퍼스트바이오, PD모델서 ‘c-Abl 저해제 효능 “논문발표”
October 29, 2021
퍼스트바이오, 파킨슨병치료제 후보물질 미국 특허 등록
August 26, 2021
퍼스트바이오, 파킨슨병치료제 후보물질 미국 특허 등록완료
June 5, 2020
퍼스트바이오, 파킨슨병치료제 후보물질 미국 특허 등록완료
June 5, 2020